İçeriğe geç

Onkoloji

Anemi (Kansızlık) Tedavisi

Eritropoezi Uyaran İlaçlar

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (yeni pencere açar)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Kaynak‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

İndeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (yeni pencere açar)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (yeni pencere açar)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Kaynak‎: Acta Haematol 2007;117(3):162-7.

İndeks‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (yeni pencere açar)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (yeni pencere açar)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Kaynak‎: Am J Hematol 2013;88(12):990-6.

İndeks‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (yeni pencere açar)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (yeni pencere açar)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Kaynak‎: J Clin Oncol 2011;29(28):3791-7.

İndeks‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (yeni pencere açar)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (yeni pencere açar)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Kaynak‎: Cancer 2012;118(3):848-55.

İndeks‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (yeni pencere açar)

Management of anemia in cancer patients. (yeni pencere açar)

Calabrich A, Katz A.

Kaynak‎: Future Oncol 2011;7(4):507-17.

İndeks‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (yeni pencere açar)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (yeni pencere açar)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Kaynak‎: BJU Int 2011;108(10):1582-7.

İndeks‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (yeni pencere açar)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (yeni pencere açar)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Kaynak‎: J Clin Oncol 2010;28(13):2239-45.

İndeks‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (yeni pencere açar)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (yeni pencere açar)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Kaynak‎: Br J Cancer 2011;105(9):1267-72.

İndeks‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (yeni pencere açar)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (yeni pencere açar)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Kaynak‎: J Intern Med 2017;281(3):284-99.

İndeks‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (yeni pencere açar)

How I treat cancer-associated anemia. (yeni pencere açar)

Gilreath JA, Rodgers GM

Kaynak‎: Blood 2020;136(7):801-13.

İndeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (yeni pencere açar)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (yeni pencere açar)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Kaynak‎: Eur J Haematol. 2023 110(4):354-61.

İndeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (yeni pencere açar)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (yeni pencere açar)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Kaynak‎: Int J Hematol 2015;102(4):401-12.

İndeks‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (yeni pencere açar)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (yeni pencere açar)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Kaynak‎: Cancer 2013;119(1):107-14.

İndeks‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (yeni pencere açar)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (yeni pencere açar)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Kaynak‎: J Natl Cancer Inst 2013;105(14):1018-26.

İndeks‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (yeni pencere açar)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (yeni pencere açar)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Kaynak‎: Cancer Sci 2013;104(4):481-5.

İndeks‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (yeni pencere açar)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (yeni pencere açar)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Kaynak‎: Br J Haematol 2019;184(2):134-60.

İndeks‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (yeni pencere açar)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (yeni pencere açar)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Kaynak‎: Support Care Cancer 2012;20(1):159-65.

İndeks‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (yeni pencere açar)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (yeni pencere açar)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Kaynak‎: Leuk Lymphoma. 2019;60(9):2324-7.

İndeks‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (yeni pencere açar)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (yeni pencere açar)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Kaynak‎: Oncologist 2010;15(9):935-43.

İndeks‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (yeni pencere açar)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (yeni pencere açar)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Kaynak‎: Lung Cancer 2012;76(3):478-85.

İndeks‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (yeni pencere açar)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (yeni pencere açar)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Kaynak‎: Eur J Haematol 2016;97(1):33-8.

İndeks‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (yeni pencere açar)

İntravenöz (Damar Yoluyla) Demir Tedavisi

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (yeni pencere açar)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Kaynak‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

İndeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (yeni pencere açar)

Intravenous iron in oncology. (yeni pencere açar)

Auerbach M, Ballard H.

Kaynak‎: J Natl Compr Canc Netw 2008;6(6):585-92.

İndeks‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (yeni pencere açar)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (yeni pencere açar)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Kaynak‎: Int J Colorectal Dis 2016;31(3):543-51.

İndeks‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (yeni pencere açar)

How I treat cancer-associated anemia. (yeni pencere açar)

Gilreath JA, Rodgers GM

Kaynak‎: Blood 2020;136(7):801-13.

İndeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (yeni pencere açar)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (yeni pencere açar)

Gilreath JA, Stenehjem DD, Rodgers GM.

Kaynak‎: J Natl Compr Canc Netw 2012;10(5):669-76.

İndeks‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (yeni pencere açar)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (yeni pencere açar)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Kaynak‎: Eur J Haematol. 2023 110(4):354-61.

İndeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (yeni pencere açar)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (yeni pencere açar)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Kaynak‎: Curr Oncol. 2023 24;30(9):7836-51.

İndeks‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (yeni pencere açar)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (yeni pencere açar)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Kaynak‎: Cochrane Database Syst Rev 2016;(2):CD009624.

İndeks‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (yeni pencere açar)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (yeni pencere açar)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Kaynak‎: World J Gastroenterol 2014;20(8):1972-85.

İndeks‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (yeni pencere açar)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (yeni pencere açar)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Kaynak‎: South Asian J Cancer. 2023 15;12(2):93-9.

İndeks‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (yeni pencere açar)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (yeni pencere açar)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Kaynak‎: J Clin Oncol 2008;26(10):1619-25.

İndeks‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (yeni pencere açar)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (yeni pencere açar)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Kaynak‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

İndeks‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (yeni pencere açar)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (yeni pencere açar)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Kaynak‎: Ann Oncol 2013;24(2):475-82.

İndeks‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (yeni pencere açar)

ONKOLOJI
Anemi (Kansızlık) Tedavisi
Türkçe
Anemi (Kansızlık) Tedavisi
https://assetsnffrgf-a.akamaihd.net/assets/ct/5a91b826b0/images/syn_placeholder_sqr.png

Hastane İrtibat Heyeti Yerel Temsilcisiyle İletişime Geçin

Yehova’nın Şahitlerini tedavi eden doktorlar bu ücretsiz bilgilendirme hizmetinden günde 24 saat yararlanabilir.

İletişime Geçin

Tıbbi Bilgilendirme Paketleri

Kan nakli yapmadan kanamanın durdurulması ve anemi tedavisi için klinik stratejiler. Yehova’nın Şahitlerinin tedaviler konusundaki dinsel ve etik ilkeleri, ayrıca Şahitlerin dünya çapındaki Hastane İrtibat Heyetleri aracılığıyla doktorlara sundukları hizmetler hakkında bilgi alabilirsiniz.

Kaynakları Göster

Videolar

Yehova’nın Şahitlerini tedavi eden uzman hekimleri ilgilendiren tedavi seçenekleri, tıbbi ve etik konular.

Videoları Görüntüle